全文获取类型
收费全文 | 3118篇 |
免费 | 213篇 |
国内免费 | 67篇 |
专业分类
耳鼻咽喉 | 7篇 |
儿科学 | 99篇 |
妇产科学 | 28篇 |
基础医学 | 353篇 |
口腔科学 | 48篇 |
临床医学 | 334篇 |
内科学 | 895篇 |
皮肤病学 | 68篇 |
神经病学 | 270篇 |
特种医学 | 287篇 |
外科学 | 441篇 |
综合类 | 54篇 |
预防医学 | 223篇 |
眼科学 | 34篇 |
药学 | 132篇 |
中国医学 | 5篇 |
肿瘤学 | 120篇 |
出版年
2022年 | 16篇 |
2021年 | 36篇 |
2020年 | 23篇 |
2019年 | 34篇 |
2018年 | 59篇 |
2017年 | 36篇 |
2016年 | 34篇 |
2015年 | 56篇 |
2014年 | 51篇 |
2013年 | 85篇 |
2012年 | 106篇 |
2011年 | 98篇 |
2010年 | 82篇 |
2009年 | 101篇 |
2008年 | 112篇 |
2007年 | 153篇 |
2006年 | 109篇 |
2005年 | 123篇 |
2004年 | 109篇 |
2003年 | 83篇 |
2002年 | 99篇 |
2001年 | 110篇 |
2000年 | 96篇 |
1999年 | 103篇 |
1998年 | 86篇 |
1997年 | 93篇 |
1996年 | 99篇 |
1995年 | 86篇 |
1994年 | 60篇 |
1993年 | 70篇 |
1992年 | 80篇 |
1991年 | 70篇 |
1990年 | 76篇 |
1989年 | 89篇 |
1988年 | 85篇 |
1987年 | 100篇 |
1986年 | 60篇 |
1985年 | 72篇 |
1984年 | 53篇 |
1983年 | 45篇 |
1982年 | 27篇 |
1981年 | 29篇 |
1980年 | 30篇 |
1979年 | 23篇 |
1978年 | 12篇 |
1977年 | 22篇 |
1976年 | 18篇 |
1975年 | 19篇 |
1974年 | 14篇 |
1973年 | 12篇 |
排序方式: 共有3398条查询结果,搜索用时 15 毫秒
91.
O. Chatzis G. Blanchard-Rohner L. Mondoulet B. Pelletier A. De Gea-Hominal M. Roux A. Huttner P.L. Hervé M. Rohr A. Matthey G. Gutknecht B. Lemaître C. Hayem H.T. Pham W. Wijagkanalan P.H. Lambert P.H. Benhamou C.A. Siegrist 《Clinical microbiology and infection》2021,27(6):878-885
ObjectivesProtection induced by acellular vaccines can be short, requiring novel immunization strategies. Objectives of this study were to evaluate safety and capacity of a recombinant pertussis toxin (PTgen) -coated Viaskin® epicutaneous patch to recall memory responses in healthy adults.MethodsThis double-blind, placebo-controlled randomized trial (Phase I) assessed the safety and immunogenicity of PTgen administered on days 0 and 14 to healthy adults using Viaskin® patches applied directly or after epidermal laser-based skin preparation. Patch administration was followed by Boostrix®dTpa on day 42. Antibodies were assessed at days 0, 14, 28, 42 and 70.ResultsAmong 102 volunteers enrolled, 80 received Viaskin-PT (Viaskin-PT 25 μg (n = 25), Viaskin-PT 50 μg (n = 25), laser + Viaskin-PT 25 μg (n = 5), laser + Viaskin-PT 50 μg (n = 25)), Viaskin-placebo (n = 10) or laser + Viaskin-placebo (n = 2). Incidence of adverse events was similar across groups (any local event: 21/25 (84.0%), 24/25 (96.0%), 4/5 (80.0%), 24/25 (96.0%), 8/10 (80.0%), 10/12 (83.0%), respectively). Direct application induced no detectable response. On day 42, PT-IgG geometric mean concentrations were significantly higher following laser + Viaskin-PT 25 μg and 50 μg (139.87 (95% CI 87.30–224.10) and 121.76 (95% CI 95.04–156.00), respectively), than laser + Viaskin-placebo (59.49, 95% CI 39.37–89.90). Seroresponse rates were higher following laser + Viaskin-PT 25 μg (4/5 (80.0%), 95% CI 28.4–99.5) and 50 μg (22/25 (88.0%), 95% CI 68.8–97.5) than laser + Viaskin-placebo (0/12 (0.0%), 95% CI 0.0–26.5).ConclusionsViaskin-PT applied after laser-based epidermal skin preparation showed encouraging safety and immunogenicity results: anti-PT booster responses were not inferior to those elicited by Boostrix®dTpa. This study is registered at ClinicalTrials.gov (NCT 03035370) and was funded by DBV Technologies. 相似文献
92.
HL Robbins M Hetzel S Mungall SJ Cawthorn 《Annals of the Royal College of Surgeons of England》2015,97(1):e1-e2
Tuberculous mastitis is rare, especially in Western countries. We describe a case where the interferon gamma release assay blood test led to diagnosis and successful treatment of the disease. 相似文献
93.
The safety of hand‐assisted laparoscopic living donor nephrectomy: The Ohio State University experience with 1500 cases 下载免费PDF全文
Hand‐assisted laparoscopic donor (HALD) nephrectomy has been performed at our institution since December 1999. Through May 2014, a total of 1500 HALD procedures have been performed. We have evaluated the outcomes of HALD. The HALD procedure consists of a hand‐port incision as well as two 12‐mm ports. Mean donor age was 40.8 ± 10.8 yr, BMI was 27.9 ± 5.0, there were 541 males, 1271 Caucasians, and the left kidney was removed in 1236 patients. All procedures were successfully completed. Four donors (0.27%) were converted to an open technique due to bleeding. Four donors required blood transfusions. 53 donors (3.5%) were readmitted in the first month post‐donation; almost half were due to gastrointestinal complaints. Six donors required reoperation; three for SBO and three for wound dehiscence. 27 patients (1.8%) developed incisional hernias. Seven donors (0.47%) developed bowel obstruction. All donors recovered well with a mean hospital stay after donation of 2.1 ± 0.3 d. All except one kidney were successfully implanted. Twenty‐one recipients (1.4%) experienced DGF. Ureter complications occurred in 17 (1.1%) recipients. Early graft loss occurred in 13 patients (0.9%). In conclusion, HALD is a safe procedure for the donor with good recipient outcomes. 相似文献
94.
95.
Production of immuno and biologically active erythropoietin was documented to occur in the human hepatoblastoma cell line HepG-2. The expression of the erythropoietin gene was further verified by Northern blot analysis using a single stranded RNA probe. In vitro studies showed that erythropoietin production by these cells was not stimulated by hypoxia or cobalt chloride, but was related to the proliferative activity of the cells in culture. In addition it was found that the secretion of erythropoietin was almost completely abrogated by tunicamycin, an inhibitor of N-linked glycosylation. This effect of tunicamycin was also observed in a permanently transfected cell line that secretes erythropoietin in large quantities. 相似文献
96.
We treated 51 patients with advanced malignant lymphoma refractory to conventional therapy with methyl-glyoxal-bis(guanylhydrazone) (methyl- GAG) at doses ranging from 400 to 800 mg/sq m. Therapy was started on a weekly schedule and was switched to every other week in responding patients at the onset of toxicity. Partial responses were observed in 6 of 13 evaluable patients with Hodgkin's disease (46%), 5 of 10 patients with diffuse poorly differentiated lymphocytic lymphoma (50%), 2 of 4 patients with nodular poorly differentiated lymphocytic lymphoma (50%), and 3 of 13 patients with diffuse histiocytic lymphoma (23%). Two of six patients with mycosis fungoides showed objective improvement in cutaneous disease. Toxicity was generally mild and included muscular weakness, myalgia, mucositis, and diarrhea; two patients developed bronchospasm following drug infusions. We conclude that methyl-GAG has major antitumor activity when administered on this schedule to patients with advanced malignant lymphoma. The low degree of toxicity, unique mechanism of action, and minimal myelosuppressive effects suggest that methyl-GAG will prove useful in future trials of combination chemotherapy regimens for the treatment of lymphoma. 相似文献
97.
G Pelletier R Capdeville H Mosnier J M Raymond J Delmont J Moreaux M Guivarch M Amouretti F X Caroli V G Levy 《Journal of hepatology》1992,16(1-2):102-105
Piezoelectric lithotripsy with the EDAP LT-01 machine combined with adjuvant bile acid therapy results in complete clearance of radiolucent gallstones in selected patients. We assessed stone recurrence rate in 84 patients with complete clearance of stone fragments and followed up at least 12 months after cessation of bile acid therapy (mean 17 months, range 12-33). Fifty-four patients had a solitary stone and 30 multiple stones. Bile acid therapy was continued for 3 months after complete fragment stones clearance which was ascertained by two consecutive ultrasound examinations. Stone recurrence was assessed by ultrasonography at 6 and 12 months, and then at least once a year. Gallstone recurrence occurred in 5 patients (6%) between 9 and 12 months with no further recurrence up to 33 months. The rate of recurrence at one year was 3.7% in patients with a solitary stone and 10% in patients with multiple stones. Only one patient with stone recurrence had recurrent biliary pain. We concluded that early gallstone recurrence rate after successful lithotripsy seems to be low in patients with solitary stones. 相似文献
98.
Development of large numbers of mast cells at sites of idiopathic chronic dermatitis in genetically mast cell-deficient WBB6F1-W/Wv mice 总被引:15,自引:1,他引:15
The normal skin and other tissues of adult mast cell-deficient WBB6F1- W/Wv or WCB6F1-Sl/Sld mice contain less than 1.0% the number of mast cells present in the corresponding tissues of the congenic normal (+/+) mice. As a result, genetically mast cell-deficient WBB6F1-W/Wv or WCB6F1-Sl/Sld mice are widely used for studies of mast cell differentiation and function. We found that mast cells developed at sites of idiopathic chronic dermatitis in WBB6F1-W/Wv mice and that the number of mast cells present in the skin of WBB6F1-W/Wv mice was proportional to the severity of the dermatitis (in ear skin, there were 33 +/- 4 mast cells/mm2 of dermis at sites of severe dermatitis v 9 +/- 3 at sites of mild dermatitis, 0.8 +/- 0.3 in skin without dermatitis, and 100 +/- 7 in the normal skin of congenic WBB6F1-+/+ mice; in back skin, the corresponding values were 2.0 +/- 0.6, 1.1 +/- 0.9, 0.025 +/- 0.025, and 26.2 +/- 3.2). The development of mast cells was a local, not systemic, consequence of the dermatitis. Thus, WBB6F1-W/Wv mice with severe dermatitis lacked mast cells in skin not showing signs of dermatitis and also in the peritoneal cavity, stomach, cecum, and tongue. Idiopathic chronic dermatitis was not associated with the local development of mast cells in WCB6F1-Sl/Sld mice, a mutant whose mast cell deficiency is due to a mechanism distinct from that of WBB6F1-W/Wv mice. These findings may have implications for understanding the nature of the mast cell deficiency in WBB6F1-W/Wv and WCB6F1-Sl/Sld mice and for the use of these mutants to analyze mast cell differentiation and function. 相似文献
99.
Histamine reduces boron neutron capture therapy‐induced mucositis in an oral precancer model 下载免费PDF全文
100.
RC Baker RAJ Spence M Boohan A Dorman M Stevenson SJ Kirk K McGlade 《The Ulster medical journal》2015,84(1):30-36